Amphastar Pharmaceuticals, Inc. (AMPH)

Amphastar Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	676.21	644.4	498.99	437.77	349.85	322.36
Revenue Growth (YoY)	30.38%	29.14%	13.98%	25.13%	8.53%	9.40%
Cost of Revenue	308.83	293.27	250.13	238.03	206.51	190.43
Gross Profit	367.38	351.12	248.86	199.74	143.34	131.92
Selling, General & Admin	84.85	80.39	66.59	68.92	65.16	63.11
Research & Development	70.97	73.74	74.77	60.93	67.23	68.85
Operating Expenses	155.82	154.13	141.36	129.85	132.39	131.96
Operating Income	211.56	196.99	107.5	69.89	10.95	-0.04
Interest Expense / Income	35.37	27.16	1.85	0.89	0.37	0.12
Other Expense / Income	-7.7	0.45	-9.21	-13.74	5.64	-62.82
Pretax Income	183.9	169.38	114.86	82.75	4.94	62.66
Income Tax	29.21	31.83	23.48	20.63	3.54	13.72
Net Income	154.69	137.55	91.39	62.12	1.4	48.94
Net Income Growth	66.04%	50.51%	47.12%	4327.37%	-97.13%	-
Shares Outstanding (Basic)	48	48	49	48	47	47
Shares Outstanding (Diluted)	53	53	52	50	49	50
Shares Change	2.01%	1.09%	5.31%	1.34%	-1.57%	7.57%
EPS (Basic)	3.20	2.85	1.88	1.30	0.03	1.04
EPS (Diluted)	2.90	2.60	1.74	1.25	0.03	0.98
EPS Growth	62.92%	49.43%	39.20%	4066.67%	-96.94%	-
Free Cash Flow	160.93	145.34	65.57	70.54	23.41	0.21
Free Cash Flow Per Share	3.34	3.01	1.35	1.48	0.50	0.00
Gross Margin	54.33%	54.49%	49.87%	45.63%	40.97%	40.92%
Operating Margin	31.29%	30.57%	21.54%	15.96%	3.13%	-0.01%
Profit Margin	22.88%	21.34%	18.31%	14.19%	0.40%	15.18%
Free Cash Flow Margin	23.80%	22.55%	13.14%	16.11%	6.69%	0.06%
Effective Tax Rate	15.88%	18.79%	20.44%	24.93%	71.62%	21.90%
EBITDA	248.86	225.48	144.03	109.09	29.46	82.87
EBITDA Margin	36.80%	34.99%	28.86%	24.92%	8.42%	25.71%
Depreciation & Amortization	29.59	28.95	27.32	25.46	24.14	20.08
EBIT	219.27	196.54	116.71	83.63	5.32	62.78
EBIT Margin	32.43%	30.50%	23.39%	19.10%	1.52%	19.48%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).